Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the FDA on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo’s Lidoderm. Watson plans to launch the product in September of 2013 pursuant with its settlement agreement with Endo Pharmaceuticals Inc. and believes that under Hatch Waxman rules, it will be entitled to 180 days of marketing exclusivity.

On May 29, 2012, Watson announced it had entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding patent litigation related to Watson’s generic version of Lidoderm. The agreement allows Watson to launch its lidocaine topical patch 5% product on September 15, 2013.

For the twelve months ending June 30, 2012, Lidoderm had total U.S. sales of approximately $1.2 billion according to IMS Health data.